publications-banner

Information about pipeline products

PublicationView

T-DXd
Lung Cancer
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
Smit EF, Felip E, Uprety D, et al.
Lancet Oncol. 2024 Apr;25(4):439-454.
Edoxaban
Other/Multi
A disposable edoxaban sensor chip using carbon paste electrode grafted with molecularly imprinted polymer
Yoshimi Y, Kani S, Aaryashree
J Artif Organs. 2024;27(1):77-81.
T-DXd
Other/Multi
Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression
Vasalou C, Proia TA, Kazlauskas L, et al.
CPT Pharmacometrics Syst Pharmacol. 2024. doi: 10.1002/psp4.13133. Epub ahead of print.
T-DXd
Breast Cancer
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
Varghese D, Cruz GI, Johanson C, et al.
Int J Clin Oncol. 2024; 29:780-789.
Dato-DXd
Lung Cancer
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan
Heist RS, Sands J, Bardia A, et al.
Cancer Treat Rev. 2024;125:102720.
Edoxaban
Cardiovascular - AF
Incidence and predictors of worsening renal function in edoxaban-treated atrial fibrillation patients within ETNA-AF-Europe registry
Gwechenberger M, Barón-Esquivias G, de Vries T, et al.
JACC: Advances. 2024;3(4):100883.
R-DXd
Other/Multi
Raludotatug deruxtecan, a CDH6-targeting antibody-drug conjugate with a DNA topoisomerase I inhibitor DXd, is efficacious in human ovarian and kidney cancer models
Suzuki H, Nagase S, Saito C, et al.
Cancer Ther. 2024;23(3):257-271.
Valemetostat
Other/Multi
Mechanisms of action and resistance in histone methylation-targeted therapy
Yamagishi M, Kuze Y, Kobayashi S, et al.
Nature. 2024;627(8002):221-228.
Pexidartinib
Other/Multi
Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA
Dharmani C, Fofah O, Wang E, et al.
Future Oncol . 2024 Feb 21. doi: 10.2217/fon-2023-0363. Online ahead of print
Edoxaban
Cardiovascular - AF
Prescribing patterns and outcomes of edoxaban in atrial fibrillation patients from Asia — one-year data from the Global ETNA-AF program
Choi J-I, Kiatchoosakun S, Jiampo P, et al.
Circ Rep. 2024;6(3):86-93.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  

footer